Document:

Amendment No. 2 to License Agreement

 Exhibit 10.4(C) 
 Execution Version 
 [***] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 Amendment Number 2 to License Agreement 
 Regents of The University of
Michigan & 
 OncoMed Pharmaceuticals, Inc. 
 Effective as of this 13 day of August, 2004, and in consideration of the mutual covenants contained herein, OncoMed Pharmaceuticals, Inc. (successor to Cancer Stem Cell Genomics, Inc.) a corporation
incorporated in the State of Delaware, with offices located at Four Embarcadero Center, Suite 2500, San Francisco, CA 94111 (“LICENSEE”), and the Regents of The University of Michigan, a constitutional corporation of the State of
Michigan (“MICHIGAN”), agree to and hereby do amend their License Agreement, dated January 5, 2001, as amended by Amendment Number 1 to License Agreement dated as of July 21, 2004 (hereinafter “Subject
License”) in accordance with the following terms and conditions: 
  

	1)	Defined Terms. Defined terms not otherwise defined in this Amendment shall have the meanings set forth in the Subject License. 

 

	2)	Licensed Field. The term “Licensed Field,” as defined in Section 30.14 of the Subject License shall be replaced in its entirety with the following
provision: 

 “Licensed Field” means cancer stem cells (including their differentiation from normal
cells), pre-neoplastic cells, related transitional cells, and non-tumorgenic cancer cells, including but not limited to (1) identification, purification, and assays thereof; (2) identification, purification, and assays of markers and
agents, or molecules, that affect the function of cancer cells as compared to other cells; and (3) information and data related to gene expression, drug discovery, diagnostics and therapeutics related thereof. 

 

	3)	Payments. Upon the earlier to occur of August 31, 2004 or fifteen (15) days following the First Funding as defined in Section 7.5 of the Subject
License, as amended by Amendment Number 1 thereto, LICENSEE will pay MICHIGAN the remaining [***] due under Section 4.1 of the Subject License. LICENSEE shall owe MICHIGAN no further payments pursuant to such Section 4.1.

  

	4)	All other terms and provisions of the Subject License shall remain unaltered and in full effect. 

[REMAINDER OF PAGE HAS INTENTIONALLY BEEN LEFT BLANK] 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their duly authorized officers or
representatives. 
  

									
	ONCOMED PHARMACEUTICALS, INC.	 		 	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
					
	By	 	 /s/ Robert F. Gavin
	 		 	By	 	 /s/ Kenneth J. Nisbet

		 	(authorized representative)	 		 		 	(authorized representative)
					
	Typed Name	 	 Robert F. Gavin
	 		 	Typed Name	 	 Kenneth J. Nisbet

					
	Title	 	 President
	 		 	Title	 	 Executive Director, UM Technology Transfer

					
	Date	 	 8/13/04
	 		 	Date	 	 8/13/04

  
 2Amendment No. 3 to License Agreement

 Exhibit 10.4(D) 

AMENDMENT NO. 3 TO LICENSE AGREEMENT 
 REGENTS OF THE UNIVERSITY OF MICHIGAN AND 
 ONCOMED PHARMACEUTICALS, INC.

 THIS AMENDMENT NO. 3 TO
THE LICENSE AGREEMENT (“Amendment”) is made effective as of March 31st, 2005 (the “Amendment Date”) and is entered into by and between THE REGENTS
OF THE UNIVERSITY OF MICHIGAN, a constitutional corporation of the State of Michigan (“Michigan”) and ONCOMED
PHARMACEUTICALS, INC., a Delaware corporation having offices at 265 N. Whisman Road, Mountain View, CA 94043 (“OncoMed”) to amend their License Agreement dated January 5, 2001, as amended by
Amendment Number 1 to the License Agreement dated as of July 21, 2004, and as amended by Amendment Number 2 to the License Agreement dated as of August 13, 2004 (“License Agreement”). 

Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings set forth in the License
Agreement. 
 WHEREAS, Michigan and OncoMed entered into the License Agreement for the
research, development and commercialization of Technology and Licensed Patents in the Licensed Field; 

WHEREAS, Michigan and OncoMed have made a Joint Invention relating to gene expression profiles of
solid tumor stem cells (OTT File No. 3097; “Methods for Treating and Diagnosing Cancer”) (“Joint Invention”) building upon the initial discovery of solid tumor stem cells (OTT File No. 1819 and USSN 09/920,517) and gene
expression profiles of solid tumor stem cells (UM 2629, PCT/US2004/018266); and, 

WHEREAS, Michigan and OncoMed intend to file a continuation-in-part patent application covering the
Joint Invention and wish to include the continuation-in-part patent application in Licensed Patents. 
 NOW,
THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Michigan and OncoMed
hereby agree as follows: 
 1. Amendment of the Agreement. 
 The parties hereby agree to amend Section 30.4 “Licensed Patents” of the License Agreement to include in Licensed Patents the continuation-in-part patent application entitled,
“Compositions and Methods for Treating and Diagnosing Cancer” covering Joint Invention. 
 Without limiting the
generality of the definition of “Licensed Patent(s)” as set forth in Section 30.4 of the License Agreement, as amended by Paragraph 1 of this Amendment, the parties agree that, as of the Amendment Date, Licensed Patents comprise the
list of patent applications set forth on Attachment B to this Amendment. 
 2. No Other Changes. Except as expressly provided in this
Amendment, all terms of the License Agreement shall remain in full force and effect. 

 3. Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be
deemed an original, but both of which together shall constitute one and the same instrument. 
 IN
WITNESS WHEREOF, the parties have caused this Amendment No. 3 to the License Agreement to be executed by their respective authorized officers. 

 

									
	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	 		 	ONCOMED PHARMACEUTICALS, INC.
					
	By:	 	    /s/ Kenneth J. Nisbet	 		 	By:	 	/s/ James N. Woody
	Name:	 	    Kenneth J. Nisbet	 		 	Name:	 	James N. Woody, M.D., Ph.D.
	Title:	 	    Executive Director, UM Technology Transfer	 		 	Title:	 	Chief Executive Officer
	Date:	 	    4/01/05	 		 	Date:	 	4/04/05

 ATTACHMENT B 

 

																							
	 File #
	 	Lic Rep	 	 Title
	 	Tech Status	 	Name	 	Department	 	Filing Date	 	 	Country	 	Application Type	 	Present Status	 	Appl #
	3097	 	Robin Rasor	 	Method for Treating and Diagnosing Cancer	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 				 		 		 		 	
	2705	 	Robin Rasor	 	Cancer Stem Cells and Notch	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 	 	2/3/04	  	 	US	 	PRV- Provisional	 	Converted	 	60/541/527
		 		 		 		 		 		 	 	2/3/05	  	 	US	 	ORD- Ordinary	 	Pending	 	11/050,282
		 		 		 		 		 		 	 	2/3/05	  	 	PCT	 	PCT-Patent Cooperation Treatry	 	Pending	 	PCT/US05/03419
	2629	 	Robin Rasor	 	Genes Expressed by Cancer Stem Cells	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 	 	6/9/03	  	 	US	 	PRV-Provisional	 	Converted	 	60/477,235
		 		 		 		 		 		 	 	6/9/03	  	 	US	 	PRV-Provisional	 	Converted	 	60/477,228
		 		 		 		 		 		 	 	6/9/04	  	 	US	 	ORD- Ordinary	 	Pending	 	10/864,207
		 		 		 		 		 		 	 	6/9/04	  	 	PCT	 	PCT-Patent Cooperation Treatry	 	Pending	 	PCT/US04/18266
	2237	 	Robin Rasor	 	Breast Cancer Stem Cells and Notch Signaling	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 	 	12/7/01	  	 	US	 	PRV-Provisional	 	Converted	 	60/338,358
		 		 		 		 		 		 	 	12/6/02	  	 	PCT	 	PCT-Patent Cooperation Treatry	 	Nationalized	 	PCT/US02/39191
		 		 		 		 		 		 	 	6/7/04	  	 	US	 	371-US from PCt as Foreign	 	pending	 	10/497,791
		 		 		 		 		 		 				 	AU	 	PCT-National Stage	 	pending	 	2002364537
		 		 		 		 		 		 				 	CA	 	PCT-National Stage	 	pending	 	2469204
		 		 		 		 		 		 				 	EP	 	PCT-National Stage	 	pending	 	2799914.3
		 		 		 		 		 		 				 	JP	 	PCT-National Stage	 	pending	 	2003-551505
	1980	 	Robin Rasor	 	An Efficient Xenograft Human Epithelial Cancer Model	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 	 	10/13/00	  	 	US	 	PRV-Provisional	 	Converted and combined
with 1819 US	 	60/240,317
	1876	 	MS-T	 	Purification of a Breast Cancer Tumor Initiating (Stem Cell)	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 				 		 		 		 	
	1819c1	 	Robin Rasor	 	Isolating and Use of Solid Tumor Stem Cells	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 	 	1/31/03	  	 	US	 	PCT-National Stage	 	Pending	 	10/343,692
	1819	 	Robin Rasor	 	Cancer Stem Cells	 	Licensed
Exclusive	 	Michael F. Clarke	 	Internal Medicine	 	 	8/3/00	  	 	US	 	PRV-Provisional	 	Converted	 	60/222,794
		 		 		 		 		 		 	 	10/13/00	  	 	US	 	PRV- Provisional	 	Converted	 	60/240,317
		 		 		 		 		 		 	 	10/13/00	  	 	US	 	PRV-Provisional	 	Converted	 	60/240,317
		 		 		 		 		 		 	 	8/2/01	  	 	PCT	 	PCT-Patent Cooperation Tratry	 	Nationalized	 	PCT/US01/24243
		 		 		 		 		 		 	 	8/1/01	  	 	US	 	ORD- Ordinary	 	Pending	 	09/920,517
		 		 		 		 		 		 	 	8/2/01	  	 	AU	 	PCT-National Stage	 	Pending	 	2001278134
		 		 		 		 		 		 	 	8/2/01	  	 	CA	 	PCT-National Stage	 	Pending	 	2417909
		 		 		 		 		 		 	 	8/2/01	  	 	EP	 	PCT-National Stage	 	Pending	 	O1956101.8
		 		 		 		 		 		 	 	8/2/01	  	 	JP	 	PCT-National Stage	 	Pending	 	2002-517738Amendment No. 4 to License Agreement

 Exhibit 10.4(E) 

Amendment No. 4 to License Agreement between 
 the Regents of The University of Michigan and 
 OncoMed Pharmaceuticals,
Inc. 
 The License Agreement dated as of January 5, 2001, as heretofore amended (the “License Agreement”),
between the REGENTS OF THE UNIVERSITY OF MICHIGAN, a constitutional corporation of the State of Michigan (“Michigan”) and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation having offices at 265 N. Whisman Road, Mountain
View, CA 94043 (“Licensee”), is hereby amended as follows: 
 1. Without limiting the generality of the definition of
“Licensed Patent(s)” set forth in Section 30.4 of the License Agreement, Licensed Patents comprise the list of patent applications, disclosures and OTT files set forth on Attachment B hereto, and Attachment B referenced in
Section 30.4 of the License Agreement is hereby amended by substituting in full Attachment B hereto. 
 2. Michigan hereby
deems any and all of the support obligations of Licensee of continued research in the laboratories of Dr. Wicha and Dr. Clarke relating to the Licensed Field as described in Section 4.6 of the License fully satisfied, and Michigan
hereby agrees that Licensee is relieved of any and all obligations to provide any payment pursuant to Section 4 of Amendment No. 1 to the License Agreement for the twelve-month period from July 21, 2004 and for any twelve-month period
thereafter. 
 3. The License Agreement, as amended by this Amendment No. 4, shall otherwise remain unaltered and in full
force and effect. 
 4. This Amendment No. 4 may be executed in counterparts, each of which shall be deemed an original,
but both of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have executed this Amendment
No. 4 by their duly authorized officers or representatives effective as of December 12, 2005. 
  

									
	 ONCOMED PHARMACEUTICALS, INC.
	 		 	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
					
	By	 	/s/ James N. Woody	 		 	By:	 	/s/ Kenneth J. Nisbet
		 	James N. Woody, M.D., Ph.D.	 		 	Name:	 	Kenneth J. Nisbet
		 	Chief Executive Officer	 		 	Title:	 	Executive Director, UM Technology Transfer

																					
	 File #
	 	 Lic Rep
	 	 Title
	 	Name	 	Department	 	Filing Date	 	 	Appl #	 	Country	 	Application Type	 	Patent Status
	 3223
	 	Robin Rasor	 	Methods for Identifying Mouse Breast Cancer Stem Cells	 	Michael F. Clarke	 	Internal Medicine Department	 	 	10/31/2005	  	 	60/731,470	 	US	 	PRV - Provisional	 	Pending
	 3222
	 	Robin Rasor	 	Methods for Treating and Diagnosing Cancer: Array Analysis of Colin and Head and Neck Cancer Stem Cells – This is a Marker	 	Michael F. Clarke	 	Internal Medicine Department	 	 	10/31/2005	  	 	60/731,465	 	US	 	PRV - Provisional	 	Pending
	 3221
	 	Robin Rasor	 	Methods for Treating and Diagnosing Cancer: Array Analysis of Colon and Head and Neck Cancer Stem Cells	 	Michael F. Clarke	 	Internal Medicine Department	 	 	10/31/2005	  	 	60/731,469	 	US	 	PRV - Provisional	 	Pending
	 3211
	 	Robin Rasor	 	Methods for Treating and Diagnosing Head and Neck Cancer	 	Michael F. Clarke	 	Internal Medicine Department	 	 	10/31/2005	  	 	60/731,279	 	US	 	PRV - Provisional	 	Pending
	 3097
	 	Robin Rasor	 	Methods for Treating and Diagnosing Cancer	 	Michael F. Clarke	 	Internal Medicine	 	 
  
	6/13/2005
 6/13/2005
	  
   
	 	60/690,003
 60/690,001
	 	US
 US
	 	PRV - Provisional	 	Pending
 Pending

	 2705
	 	Robin Rasor	 	Cancer Stem Cells and Notch	 	Michael F. Clarke	 	Internal Medicine	 	 
  
  
	02/03/2004
 02/03/2005

02/03/2005
	  
   

  
	 	60/541,527
 11/050,282

PCT/US05/03419
	 	US
 US
 PCT
	 	PRV - Provisional
 ORD - Ordinary

PCT - Patent Cooperation Treaty
	 	Pending
 Pending

Pending

	 2629
	 	Robin Rasor	 	Genes Expressed by Cancer Stem Cells	 	Michael F. Clarke	 	Internal Medicine	 	 
  
  
  
	06/09/2003
 06/09/2003

06/09/2004

06/09/2004
	  
   

  
   
	 	60/477,235
 60/477,228

10/864,207
 PCT/US04/18266
	 	US
 US
 US
 PCT
	 	PRV - Provisional
 PRV - Provisional

ORD - Ordinary

PCT - Patent Cooperation Treaty
	 	Converted
 Converted

Pending
 Pending

	 2237
	 	Robin Rasor	 	Breast Cancer Stem Cells and Notch Signaling	 	Michael F. Clarke	 	Internal Medicine	 	 
  
  
  
  
  
  
	12/07/2001
 12/06/2002

10/29/2004

12/06/2002

12/06/2002

12/06/2002

12/06/2002
	  
   

  
   

  
   

  
	 	60/338,358
 PCT/US02/39191

10/497,791
 2002364537

2469204
 02799914.3

2003-551505
	 	US
 PCT
 US
 AU
 CA
 EP
 JP
	 	PRV - Provisional

PCT - Patent Cooperation Treaty
 371 - US from PCT as Foreign
 PCT - Nat. Stg.

PCT - Nat. Stg.
 PCT - Nat. Stg.

PCT - Nat. Stg.
	 	Converted
 Nationalized

Pending
 Pending

Pending
 Pending

Pending

	 1980
	 	Robin Rasor	 	An Efficient Xenograft Human Epithelial Cancer Model	 	Michael F. Clarke	 	Internal Medicine	 	 
  
  
	10/13/2000
 08/02/2001

08/01/2001
	  
   

  
	 	60/240,317
 PCT/US01/24243

09/920,517
	 	US
 PCT
 US
	 	PRV - Provisional

PCT - Patent Cooperation Treaty
 ORD - Ordinary
	 	Converted
 Nationalized

Allowed

	 1876
	 	Robin Rasor	 	Purification of a Breast Cancer Tumor Initiating (Stem) Cell	 	Michael F. Clarke	 	Internal Medicine	 	 
  
	08/02/2001
 08/01/2001
	  
   
	 	PCT/US01/24243
 09/920,517
	 	PCT
 US
	 	PCT - Patent Cooperation Treaty
 ORD -
Ordinary
	 	Nationalized
 Allowed

	 1819c1
	 	Robin Rasor	 	Isolation and Use of Solid Tumor Stem Cells	 	Michael F. Clarke	 	Internal Medicine	 	 	1/31/2003	  	 	10/343,692	 	US	 	371 - US from PCT as Foreign	 	Pending
	 1819    
	 	Robin Rasor	 	Cancer Stem Cells                         
                                         
  	 	Michael F. Clarke	 	Internal Medicine                    	 	 
  
  
  
  
  
  
  
  
  
  
  
  
	08/03/2000
 10/13/2000

08/02/2001
 08/01/2001

08/02/2001
 08/02/2001

08/02/2001
 08/02/2001

01/31/2003
 06/10/2005

06/10/2005
 00/00/0000

00/00/0000
	  
   

  
   

  
   

  
   

  
   

  
   

  
	 	60/222,794
 60/240,317

PCT/US01/24243
 09/920,517

2001278134
 2417909

01956101.8
 2002-517738

10/343,692
 11/150,073

11/150,524
	 	US
 US
 PCT
 US
 AU
 CA
 EP
 JP
 US
 US
 US
 US
 US
	 	PRV - Provisional

PRV - Provisional

PCT - Patent Cooperation Treaty
 ORD - Ordinary
 PCT - Nat. Stg.
 PCT - Nat. Stg.
 PCT - Nat. Stg.
 PCT - Nat. Stg.
 371 - US from PCT as Foreign

DIV - Divisional
 DIV - Divisional

DIV - Divisional
 DIV -
Divisional
	 	Converted
 Converted

Nationalized
 Allowed

Pending
 Pending

Pending
 Pending

Pending
 Pending

Pending
 Not Yet Filed

Not Yet Filed

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]